Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis
Key facts
- Who runs it
- University of Minnesota
- Where
- Uganda2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 48 people enrolled
- Started
- 9 Apr 2024
- Ended
- 2 Oct 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- AMBITION trial control
- Flucytosine
- Record updated
- 27 August 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- CSF cryptococcal antigen (CrAg) positive meningitis
- Ability and willingness to provide informed consent
- Willing to receive protocol-specified lumbar punctures
Who cannot take part
- Receiving chemotherapy or corticosteroids
- Patients with prior 5-flucytosine exposure >3 days in the 12 months prior to enrollment
- Suspected Paradoxical immune reconstitution inflammatory syndrome (IRIS)
- Any condition for which participation would not be in the best interest of the participant or that could limit protocol specified assessments
- Absolute neutrophil count <500 x10 6 cells/L
- Age <18 years
- Inability to take enteral (oral or nasogastric) medicine
- Cannot or unlikely to attend regular clinic visits
- Pregnancy or breastfeeding
- CrCl < 20 mL/minute
- Thrombocytopenia < 50,000 x 10 6 cells/L
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Cryptococcal meningitis (CM) is a fungal infection that causes a severe syndrome of meningitis that is 100% fatal without antifungal therapy. Even with antifungal therapy, mortality rates remain high, especially in Africa where the ongoing HIV/AIDS pandemic leads to higher prevalence of cryptococcosis. Combination of amphotericin and flucytosine (5-FC) is the mainstay of therapy for the initial management of CM. Indeed, it has even been shown that effective delivery of these therapies in Africa can lower mortality rates by 90%.
Read full original descriptionShow less
This is a prospective open-label trial to compare the efficacy and safety of lower doses of 5FC during induction therapy to historical controls with standard 5FC dosing. Participants in the trial will receive 60mg/kg/day of 5-FC in 3 divided doses for 10 days. Single-dose liposomal amphotericin (10mg/kg) is preferred, if available. Amphotericin B 0.7-1.0 mg/kg/day may be used if needed. Historical controls drawn from the AMBITION trial will be used as a comparison group, selected weighted by inclusion/exclusion criteria, baseline characteristics and therapies received. Induction therapy for control group participants followed the 2018 WHO cryptococcal guidelines with 7 days of 5-FC 100mg/kg/day and 7 days of IV Amphotericin deoxycholate followed by 1200mg fluconazole/day for 7 days. The intervention group received single- dose liposomal amphotericin plus 5-FC and fluconazole 1200 mg/day.
All participants will receive fluconazole 1200mg/day during consolidation therapy from day 1 to 14 then 800mg/day from day 15 to 10 weeks, and 200mg/day after 10 weeks. All participants will receive lumbar punctures at diagnosis, day 3, day 5-7, day 10-14, and additionally as required for control of intracranial pressure and documentation of CSF sterilization. Controls from Ambition will be matched for the same LP windows. Therapeutic LPs conducted during the first week have a ~70% relative survival benefit.
The 2 groups in the trial
- controlExisting treatment, for comparison
Historical controls drawn from the AMBITION trial will be used as a comparison group, selected weighted by inclusion/exclusion criteria, baseline characteristics and therapies received.
Treatment: AMBITION trial control
- Low Dose FlucytosineTreatment being tested
HIV-infected persons in Uganda with cryptococcal meningitis
Treatment: Flucytosine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026
- Record updated
- 27 August 2025